Literature DB >> 16268666

The use of triptans in the management of menstrual migraine.

Lisa K Mannix1, Julia A Files.   

Abstract

Many women experience headaches, including migraine, in association with their menstrual cycles. Although definitions vary, menstrual migraine generally refers to migraine without aura that occurs within several days prior to and several days after the onset of menses. Although menstrual migraine has been reported to be more difficult to treat than other types of migraines, there is no evidence from controlled clinical trials to support this assertion. Thus, the pharmacological treatment of menstrual migraine should be similar to that of other types of migraines, except with respect to the use of hormonal manipulations to treat menstrual migraine. Serotonin 5-HT(1B/1D) receptor agonists (triptans) are effective for the acute treatment of both menstrual and non-menstrual migraines. When used as acute therapy, a triptan should be administered early, when the headache is still mild in severity. Ideally, an acute therapy will provide rapid and complete pain relief with no disability. Some patients may require preventive therapy for menstrual migraine based on suboptimal response to an adequate trial of acute therapy. Patient diaries that record headache onset, relationship to the menstrual cycle and treatment response through three complete cycles will allow accurate prediction of the onset of menstrual migraine; this information is also needed to make decisions about timing of intermittent preventive therapy. The goals of intermittent preventive therapy are to reduce the frequency, duration and intensity of menstrual migraine attacks. Clinical studies show that triptans are effective when used as either acute therapy or as intermittent preventive therapy for menstrual migraine. Sumatriptan and zolmitriptan have been evaluated in prospective, randomised, controlled trials for acute treatment. Retrospective analyses and open-label studies also support the use of other triptans as acute therapy. In addition, sumatriptan, frovatriptan, naratriptan and zolmitriptan have been evaluated as intermittent preventive therapy in prospective studies. Thus, data from clinical studies indicate that triptans are effective for the treatment of menstrual migraine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16268666     DOI: 10.2165/00023210-200519110-00005

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  72 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

Review 2.  Oral contraceptives and stroke.

Authors:  M G Bousser; S J Kittner
Journal:  Cephalalgia       Date:  2000-04       Impact factor: 6.292

3.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

Review 4.  Menstrual migraine: diagnosis and treatment.

Authors:  C L Lay; A M Mascellino
Journal:  Curr Pain Headache Rep       Date:  2001-04

5.  Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials.

Authors:  R K Cady; F Sheftell; R B Lipton; S O'Quinn; M Jones; D G Putnam; A Crisp; A Metz; S McNeal
Journal:  Clin Ther       Date:  2000-09       Impact factor: 3.393

Review 6.  Management of menstrual migraine.

Authors:  C A Boyle
Journal:  Neurology       Date:  1999       Impact factor: 9.910

7.  Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine.

Authors:  Robert Nett; Steve Landy; Steve Shackelford; Mary S Richardson; Michael Ames; Michelle Lener
Journal:  Obstet Gynecol       Date:  2003-10       Impact factor: 7.661

8.  A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.

Authors:  Stephen D Silberstein; Arthur H Elkind; Curtis Schreiber; Charlotte Keywood
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

9.  Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan.

Authors:  M P Solbach; R S Waymer
Journal:  Obstet Gynecol       Date:  1993-11       Impact factor: 7.661

10.  Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women.

Authors:  F Granella; G Sances; C Zanferrari; A Costa; E Martignoni; G C Manzoni
Journal:  Headache       Date:  1993 Jul-Aug       Impact factor: 5.887

View more
  11 in total

1.  Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.

Authors:  Michael Tuchman; Angela Hee; Ugochi Emeribe; Stephen Silberstein
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  A review of the use of frovatriptan in the treatment of menstrually related migraine.

Authors:  Gianni Allais; Chiara Benedetto
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

3.  Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study.

Authors:  Michael M Tuchman; Angela Hee; Ugochi Emeribe; Stephen Silberstein
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan.

Authors:  Gianni Allais; Gennaro Bussone; Gisella Airola; Paola Borgogno; Ilaria Castagnoli Gabellari; Cristina De Lorenzo; Elena Pavia; Chiara Benedetto
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

5.  Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers.

Authors:  Andrew Wade; Stephen Pawsey; Holly Whale; Malcolm Boyce; Steve Warrington
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

6.  Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan.

Authors:  Gianni Allais; Vincenzo Tullo; Chiara Benedetto; Dario Zava; Stefano Omboni; Gennaro Bussone
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

7.  Remission of hypnic headache associated with idiopathic cyclic edema with the use of aminaphtone.

Authors:  José Maria Pereira de Godoy
Journal:  Open Neurol J       Date:  2010-09-06

8.  Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan.

Authors:  Lidia Savi; Stefano Omboni; Carlo Lisotto; Giorgio Zanchin; Michel D Ferrari; Dario Zava; Lorenzo Pinessi
Journal:  J Headache Pain       Date:  2011-08-13       Impact factor: 7.277

9.  Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies.

Authors:  Gianni Allais; Vincenzo Tullo; Stefano Omboni; Chiara Benedetto; Grazia Sances; Dario Zava; Michel D Ferrari; Gennaro Bussone
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

10.  Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study.

Authors:  Marco Bartolini; Maria Adelaide Giamberardino; Carlo Lisotto; Paolo Martelletti; Davide Moscato; Biagio Panascia; Lidia Savi; Luigi Alberto Pini; Grazia Sances; Patrizia Santoro; Giorgio Zanchin; Stefano Omboni; Michel D Ferrari; Brigida Fierro; Filippo Brighina
Journal:  J Headache Pain       Date:  2012-05-17       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.